We are a multidisciplinary team of researchers and physicians at UCSF, UC Berkeley, Chan Zuckerberg Biohub, and Innovative Genomics Institute.
Antibody tests for prior exposure to SARS-CoV-2 virus are urgently needed. We are performing head-to-head comparisons of commercially available lateral flow assays (also known as rapid serology tests) and ELISA immunoassays. Importantly, we include an evaluation of test performance by time from symptom onset. Our goal is to provide an ongoing resource for reliable tests to inform the scientific and medical community, policy makers, and the general public.
April 24, 2020: Read our pre-print manuscript. This is a preliminary report of work that has not been certified by peer review. This should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information
April 29, 2020: The manuscript is now on MedRxiv.
For % Positivity, samples were from SARS-CoV-2 PCR-positive patients. For Specificity, we included pre-COVID-19 negative controls from American Red Cross blood donors. If a test gives separate IgG and IgM data, that data is presented alongside the overall positivity (IgG +/or IgM) data.